Simon Cooper

Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trials

Susan Manzi, Jorge Sánchez‐Guerrero, Joan T. Merrill et al. · Annals of the Rheumatic Diseases · 2012 · 396 citations · Full text

Safety and efficacy of additional courses of rituximab in patients with active rheumatoid arthritis: An open‐label extension analysis

Edward Keystone, Roy Fleischmann, Paul Emery et al. · Arthritis & Rheumatism · 2007 · 334 citations

Secukinumab administration by pre-filled syringe: efficacy, safety and usability results from a randomized controlled trial in psoriasis (FEATURE)

Andrew Blauvelt, Jörg C. Prinz, Alice B. Gottlieb et al. · British Journal of Dermatology · 2014 · 317 citations

Effect of belimumab treatment on renal outcomes: results from the phase 3 belimumab clinical trials in patients with SLE

MA Dooley, Frédéric Houssiau, Cynthia Aranow et al. · Lupus · 2012 · 262 citations · Full text

Renal Parameters, Dialysis Therapy, Nephrology +19

Safety profile of belimumab: pooled data from placebo-controlled phase 2 and 3 studies in patients with systemic lupus erythematosus

DJ Wallace, Sandra Navarra, M. Pétri et al. · Lupus · 2012 · 118 citations